We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+24.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$2.23B
AUM Growth
+$544M
Cap. Flow
+$302M
Cap. Flow %
13.53%
Top 10 Hldgs %
63.09%
Holding
48
New
6
Increased
13
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$145M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$29.8M
3
PACB icon
Pacific Biosciences
PACB
+$25.9M
4
BLFS icon
BioLife Solutions
BLFS
+$21.4M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$19.3M

Top Sells

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$12.3M
2
BLUE
bluebird bio
BLUE
+$11.4M
3
VYGR icon
Voyager Therapeutics
VYGR
+$9.46M
4
CDXS icon
Codexis
CDXS
+$8.82M
5
ZYME icon
Zymeworks
ZYME
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 80.87%
2 Materials 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
1
DELISTED
Invitae Corporation
NVTA
$392M 17.54%
9,033,943
– –
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$169M 7.57%
5,840,107
+990,583
+20% +$21.4M
RLAY icon
3
Relay Therapeutics
RLAY
$4.04B
$162M 7.26%
+3,808,894
New +$145M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$144M 6.43%
1,550,000
– –
FATE icon
5
Fate Therapeutics
FATE
$294M
$122M 5.46%
3,050,000
– –
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$119M 5.31%
870,000
– –
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$29.1B
$90.3M 4.04%
620,000
+70,000
+13% +$9.95M
TWST icon
8
Twist Bioscience
TWST
$5.97B
$76M 3.4%
1,000,000
– –
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.63B
$74.4M 3.33%
530,000
– –
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$61.3M 2.74%
1,750,000
+680,000
+64% +$29.8M
RVMD icon
11
Revolution Medicines
RVMD
$38.8B
$56.9M 2.55%
1,634,535
+299,999
+22% +$8.31M
GBIO
12
DELISTED
Generation Bio
GBIO
$49.8M 2.23%
161,121
– –
BLUE
13
DELISTED
bluebird bio
BLUE
$49.4M 2.21%
70,638
-14,668
-17% -$11.4M
BNR
14
Burning Rock Biotech
BNR
$95M
$48.2M 2.16%
192,215
+19,136
+11% +$4.53M
DNLI icon
15
Denali Therapeutics
DNLI
$3.67B
$46.9M 2.1%
1,310,000
– –
CDXS icon
16
Codexis
CDXS
$157M
$46.8M 2.09%
3,985,000
-707,732
-15% -$8.82M
CDNA icon
17
CareDx
CDNA
$2.48B
$45.3M 2.03%
1,193,335
– –
PACB icon
18
Pacific Biosciences
PACB
$444M
$44.4M 1.99%
+4,500,000
New +$25.9M
ONC
19
BeOne Medicines Ltd
ONC
$32.3B
$43M 1.92%
150,000
– –
ALLO icon
20
Allogene Therapeutics
ALLO
$632M
$35.6M 1.6%
945,000
+320,000
+51% +$12.1M
ADPT icon
21
Adaptive Biotechnologies
ADPT
$3.71B
$34.7M 1.55%
713,125
– –
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
$28.3M 1.27%
275,000
+88,500
+47% +$13.3M
DNTH icon
23
Dianthus Therapeutics
DNTH
$5.72B
$22.8M 1.02%
209,127
– –
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.86B
$22.3M 1%
266,430
– –
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
$21.8M 0.98%
395,000
+95,000
+32% +$6.04M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Casdin Capital held 48 positions worth $2.23B, up 32% from $1.69B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital deployed $302M of net new capital in Q3 2020, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Relay Therapeutics: 3,808,894 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was bluebird bio, an estimated $11.4M trimmed.

  • Casdin Capital's largest Q3 2020 buy was Relay Therapeutics: 3,808,894 shares worth $162M.
  • Casdin Capital added most to Agios Pharmaceuticals in Q3 2020, an estimated $29.8M increase.
  • Casdin Capital's biggest Q3 2020 reduction was bluebird bio, cutting an estimated $11.4M.
  • Casdin Capital fully exited Gritstone bio, Inc. Common Stock in Q3 2020, selling an estimated $12.3M.
  • Casdin Capital's ten largest holdings make up 63% of its $2.23B portfolio in Q3 2020.
  • Casdin Capital opened 6 new positions and closed 3 in Q3 2020.
  • Casdin Capital's portfolio value rose 32% quarter-over-quarter to $2.23B.

Based on Casdin Capital's 13F filing for Q3 2020, filed 16 Nov 2020.